136 related articles for article (PubMed ID: 25747275)
1. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance.
Khalil HS; Mitev V; Vlaykova T; Cavicchi L; Zhelev N
J Biotechnol; 2015 May; 202():40-9. PubMed ID: 25747275
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.
Zoja C; Casiraghi F; Conti S; Corna D; Rottoli D; Cavinato RA; Remuzzi G; Benigni A
Arthritis Rheum; 2007 May; 56(5):1629-37. PubMed ID: 17469145
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM; Gianella-Borradori A
Expert Opin Investig Drugs; 2005 Apr; 14(4):457-77. PubMed ID: 15882121
[TBL] [Abstract][Full Text] [Related]
4. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Kokkinos MI; Thomas H
Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
[TBL] [Abstract][Full Text] [Related]
5. Seliciclib in malignancies.
Aldoss IT; Tashi T; Ganti AK
Expert Opin Investig Drugs; 2009 Dec; 18(12):1957-65. PubMed ID: 19938906
[TBL] [Abstract][Full Text] [Related]
6. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.
Whittaker SR; Te Poele RH; Chan F; Linardopoulos S; Walton MI; Garrett MD; Workman P
Cell Cycle; 2007 Dec; 6(24):3114-31. PubMed ID: 18075315
[TBL] [Abstract][Full Text] [Related]
7. Treatment with a cyclin-dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental glomerulonephritis.
Sheryanna AM; Smith J; Bhangal G; Barnett A; McClue S; Tam FW; Cook T; Pusey CD
Nephrology (Carlton); 2011 May; 16(4):410-6. PubMed ID: 21518118
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
Lacrima K; Rinaldi A; Vignati S; Martin V; Tibiletti MG; Gaidano G; Catapano CV; Bertoni F
Leuk Lymphoma; 2007 Jan; 48(1):158-67. PubMed ID: 17325859
[TBL] [Abstract][Full Text] [Related]
9. Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib.
Iurisci I; Filipski E; Sallam H; Harper F; Guettier C; Maire I; Hassan M; Iacobelli S; Lévi F
Chronobiol Int; 2009 Aug; 26(6):1169-88. PubMed ID: 19731111
[TBL] [Abstract][Full Text] [Related]
10. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.
Galimberti F; Thompson SL; Liu X; Li H; Memoli V; Green SR; DiRenzo J; Greninger P; Sharma SV; Settleman J; Compton DA; Dmitrovsky E
Clin Cancer Res; 2010 Jan; 16(1):109-20. PubMed ID: 20028770
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Liebl J; Krystof V; Vereb G; Takács L; Strnad M; Pechan P; Havlicek L; Zatloukal M; Fürst R; Vollmar AM; Zahler S
Angiogenesis; 2011 Sep; 14(3):281-91. PubMed ID: 21487803
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
[TBL] [Abstract][Full Text] [Related]
13. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.
Appleyard MV; O'Neill MA; Murray KE; Paulin FE; Bray SE; Kernohan NM; Levison DA; Lane DP; Thompson AM
Int J Cancer; 2009 Jan; 124(2):465-72. PubMed ID: 19003963
[TBL] [Abstract][Full Text] [Related]
14. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
[TBL] [Abstract][Full Text] [Related]
15. Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.
Iurisci I; Filipski E; Reinhardt J; Bach S; Gianella-Borradori A; Iacobelli S; Meijer L; Lévi F
Cancer Res; 2006 Nov; 66(22):10720-8. PubMed ID: 17108108
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
Wilson SC; Atrash B; Barlow C; Eccles S; Fischer PM; Hayes A; Kelland L; Jackson W; Jarman M; Mirza A; Moreno J; Nutley BP; Raynaud FI; Sheldrake P; Walton M; Westwood R; Whittaker S; Workman P; McDonald E
Bioorg Med Chem; 2011 Nov; 19(22):6949-65. PubMed ID: 21982796
[TBL] [Abstract][Full Text] [Related]
17. Effect of seliciclib (CYC202, R-roscovitine) on lymphocyte alloreactivity and acute kidney allograft rejection in rat.
Pezzotta A; Mister M; Monteferrante G; Cassis L; Azzollini N; Aiello S; Satta M; Benigni A; Remuzzi G; Noris M
Transplantation; 2008 May; 85(10):1476-82. PubMed ID: 18497689
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.
Hui AB; Yue S; Shi W; Alajez NM; Ito E; Green SR; Frame S; O'Sullivan B; Liu FF
Clin Cancer Res; 2009 Jun; 15(11):3716-24. PubMed ID: 19470731
[TBL] [Abstract][Full Text] [Related]
20. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
